![]() Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex: Stock Symbol: GNPXGenprex Stock Symbol: GNPX is Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes
By: Corporate Ads The GNPX lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of GNPX lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes On September 4th GNPX announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D). This decision was made public on September 4, 2024. The planned spin-out transaction would allow both GNPX and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The GNPX spin-out, would result in NewCo focusing on developing GPX-002, while GNPX would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates a strong ongoing commitment to the GNPX streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024. The GNPX goal for separating the diabetes clinical development program from its oncology program follows closely behind a recent announcement to re-focus the GNPX oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, GNPX continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, GNPX is considering various strategic alternatives and opportunities to enhance stockholder value. Presentations to Highlight Gene Therapies for Cancer and Diabetes GNPX has announced its participation in the following upcoming investor and industry conferences: Event: H.C. Wainwright 26th Annual Global Investment Conference Conference Dates: September 9-13, 2024 Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual) Event: Chardan's 8th Annual Genetic Medicines Conference Dates: September 30 – October 1, 2024 Location: Westin Grand Central in New York, NY New Video Featuring GNPX Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials On August 15th GNPX released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the GNPX oncology clinical development program. To watch the video, visit the GNPX website at: https://www.genprex.com/ The Acclaim-1 clinical trial is evaluating the combination of the GNPX lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso. The Acclaim-3 clinical trial is evaluating the combination of REQORSA and GNPX Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Media Contact: Company Name: Genprex, Inc. Contact: Kalyn Dabbs Email: media@genprex.com Phone: (877) 774-GNPX (4679) Country: United States Website: www.genprex.com DISCLAIMER: https://corporateads.com/ Disclosure listed on the CorporateAds website Contact Corporate Ads ***@gmail.com Photos: https://www.prlog.org/ https://www.prlog.org/ https://www.prlog.org/ https://www.prlog.org/ End
|